gantenerumab   Click here for help

GtoPdb Ligand ID: 6933

Synonyms: R-1450 | RG-1450 | Ro-4909832
Compound class: Antibody
Comment: Gantenerumab targets aggregated forms of human amyloid β (Aβ) proteins Aβ42 and Aβ40. This is in contrast to solanezumab which targets soluble Aβ.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Protein sequence analysis reveals that gantenerumab is likely to be clone #7.9.H7 in patent US7794719 [1].
No information available.
Summary of Clinical Use Click here for help
May be useful in the treatment of Alzheimer's disease [3]. In phase 1 trials treatment caused reduced brain amyloid β levels, but was associated with the unwanted side effect of vasogenic edema. Phase 3 trial is underway with results expected in 2015.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01760005 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Phase 2/Phase 3 Interventional Washington University School of Medicine